Announced
Completed
Financials
Sources
RNS Announcement
Consort Medical -
Publication of Offer Document
Recipharm -
Offer Extension and Acceptance Level Update
Recipharm -
Offer Update - German Competition Clearance
Recipharm -
Offer Update
Recipharm -
No Extension or Increase & Irish CCPC Clearance
Recipharm -
Offer Extension and Acceptance Level Update
Recipharm -
Notice of Cancellation of Listing
Recipharm -
Compulsory acquisition of Consort Shares
Recipharm -
Press Release
Recipharm -
Delisting and Cancellation of Trading
Recipharm -
RNS Announcement
Recipharm -
Tags
Pharmaceuticals
Single Bidder
United Kingdom
Friendly
pharmaceutical development
Acquisition
Public
Majority
Completed
Privatisation
Cross Border
Synopsis
Recipharm Group, a Swedish pharmaceutical group, completed the acquisition of Consort Medical, a contract development and pharmaceutical manufacturing company, for $809m. "I am excited at the prospect of combining Recipharm with Consort which is extremely complementary. In our view Bespak is already acknowledged as a leading drug device developer and manufacturer and is a perfect fit for Recipharm's broader pharmaceutical capabilities. The enlarged group will be able to provide finished dose forms in Bespak's key technologies, and provide customers with a far more integrated approach. The Aesica business will further expand our capabilities and capacities in both API and finished dose manufacturing whilst providing access to a new customer base," Thomas Eldered, Recipharm Group CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.